Endocannabinoids in nervous system health and disease: The big picture in a nutshell

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 367, Issue 1607, 2012, Pages 3193-3200

  Skaper, Stephen D ^a   Di Marzo, Vincenzo ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

Author keywords

Development; Endocannabinoids; Immune modulation; Neurodegeneration; Pain; Synaptic plasticity

Indexed keywords

EID: 84868129085     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2012.0313     Document Type: Article

References (53)

1. Booth, M. 2003 Cannabis: a history. London, UK: Doubleday.
2. Elphick, M. R. & Egertová, M. 2001 The neurobiology and evolution of cannabinoid signalling. Phil. Trans. R. Soc. Lond. B 356, 381-408.(do:10.1098/rstb.2000.0787)
3. Elphick, M. R. 2012 The evolution and comparative neurobiology of endocannabinoid signalling. Phil. Trans. R. Soc. B 367, 3201-3215. (do:10.1098/rstb.2011.0394)
4. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564. (do:10.1038/346561a0)
5. Munro, S., Thomas, K. L. & Abu-Shaar, M. 1993 Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65. (do:10.1038/365061a0)
6. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sørgård, M., Di Marzo, V., Julius, D. & Högestätt, E. D. 1999 Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457. (do:10.1038/22761)
7. Di Marzo, V. & De Petrocellis, L. 2012 Why do cannabinoid receptors have more than one endogenous ligand? Phil. Trans. R. Soc. B 367, 3216-3228. (do:10.1098/rstb.2011.0382)
8. De Petrocellis, L. & Di Marzo, V. 2011 Cell signalling: why fasting worms age slowly. Nature 473, 161-163. (doi:10.1038/473161a)
9. Walsh, F. S. & Skaper, S. D. 1998 Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration. Mol. Cell. Neurosci. 12, 179-193.(doi:10.1006/mcne.1998.0714)
10. Guillemot, F., Molnar, Z., Tarabykin, V. & Stoykova, A. 2006 Molecular mechanisms of cortical differentiation. Eur. J. Neurosci. 23, 857-868. (doi:10.1111/j.1460-9568.2006.04626.x)
11. Puighermanal, E., Busquets-Garcia, A., Maldonado, R. & Ozaita, A. 2012 Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Phil. Trans. R. Soc. B 367, 3254-3263. (doi:10.1098/rstb.2011.0384)
12. Melis, M. & Pistis, M. 2012 Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Phil. Trans. R. Soc. B 367, 3276-3285. (doi:10.1098/rstb.2011.0383)
13. Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A. & Guimarães, F. S. 2012 Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Phil. Trans. R. Soc. B 367, 3364-3378. (doi:10.1098/rstb.2011.0389)
14. Díaz-Alonso, J., Guzmán, M. & Galve-Roperh, I. 2012 Endocannabinoids via CB1 receptors act as neurogenic niche cues during cortical development. Phil. Trans. R. Soc. B 367, 3229-3241. (doi:10.1098/rstb.2011.0385)
15. Wilson, R. I. & Nicoll, R. A. 2001 Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592. (doi:10.1038/35069076)
16. Ohno-Shosaku, T., Maejima, T. & Kano, M. 2001 Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29, 729-738. (doi:1016/S0896-6273(01)00247-1)
17. Kreitzer, A. C. & Regehr, W. G. 2001 Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29, 717-727. (doi:1016/S0896-6273(01)00246-X)
18. Cachope, R. 2012 Functional diversity on synaptic plasticity mediated by endocannabinoids. Phil. Trans. R. Soc. B 367, 3242-3253. (doi:10.1098/rstb.2011.0386)
19. Davies, S. N., Pertwee, R. G. & Riedel, G. 2002 Functions of cannabinoid receptors in the hippocampus. Neuropharmacology 42, 993-1007. (doi:10.1016/S0028-3908(02)00060-6)
20. Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M. & Watanabe, M. 2009 Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 89, 309-380. (doi:10.1152/physrev.00019.2008)
21. Navarrete, M. & Araque, A. 2010 Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68, 113-126. (doi:10.1016/j.neuron.2010.08.043)
22. Bènard, G. et al. 2012 Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat. Neurosci. 15, 558-564. (doi:10.1038/nn.3053)
23. Kamprath, K., Romo-Parra, H., Häring, M., Gaburro, S., Doengi, M., Lutz, B. & Pape, H. C. 2011 Short-term adaptation of conditioned fear responses through endocannabinoid signaling in the central amygdala. Neuropsychopharmacology 36, 652-663. (doi:10.1038/npp.2010.196)
24. Marsicano, G. et al. 2002 The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534. (doi:10.1038/nature00839)
25. Ramikie, T. S. & Patel, S. 2011 Endocannabinoid signaling in the amygdala: anatomy, synaptic signaling, behavior, and adaptations to stress. Neuroscience 204, 38-52. (doi:10.1016/j.neuroscience.2011.08.037)
26. Brose, N., Betz, A. & Wegmeyer, H. 2004 Divergent and convergent signaling by the diacylglycerol second messenger pathway in mammals. Curr. Opin. Neurobiol. 14, 328-340. (doi:10.1016/j.conb.2004.05.006)
27. Carrasco, S. & Merida, I. 2007 Diacylglycerol, when simplicity becomes complex. Trends Biochem. Sci. 32, 27-36. (doi:10.1016/j.tibs.2006.11.004)
28. Reisenberg, M., Singh, P. K., Williams, G. & Doherty, P. 2012 The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling. Phil. Trans. R. Soc. B 367, 3264-275. (doi:10.1098/rstb.2011.0387)
29. Melis, M., Muntoni, A. L. & Pistis, M. 2012 Endocannabinoids and the processing of value-related signals. Front. Pharmacol. 3, 7. (doi:10.3389/fphar.2012.00007)
30. Melis, M. et al. 2006 Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol. Dis. 24, 15-27. (doi:10.1016/j.nbd.2006.04.010)
31. Pistis, M. & Melis, M. 2010 From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr. Med. Chem. 17, 1450-1467. (doi:10.2174/092986710790980014)
32. Wise, R. A. 1981 Intracranial self-stimulation: mapping against the lateral boundaries of the dopaminergic cells of the substantia nigra. Brain Res. 213, 190-194. (doi:10.1016/0006-8993(81)91260-9)
33. Reynolds, J. N., Hyland, B. I. & Wickens, J. R. 2001 A cellular mechanism of reward-related learning. Nature413, 67-70. (doi:10.1038/35092560)
34. Schultz, W. & Dickinson, A. 2000 Neuronal coding of prediction errors. Annu. Rev. Neurosci. 23, 473-500. (doi:10.1038/35044563)
35. Milligan, E. D. & Watkins, L. R. 2009 Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 10, 23-36. (doi:10.1038/nrn2533)
36. Nightingale, S. 2012 The neuropathic pain market. Nat. Rev. Drug Discov. 11, 101-102. (doi:10.1038/nrd3624)
37. Starowicz, K. & Przewlocka, B. 2012 Modulation of neuropathic-pain-related behavior by the spinal endocannabinoid/ endovanilloid system. Phil. Trans. R. Soc. B367, 3286-3299. (doi:10.1098/rstb.2011.0392)
38. Sagar, D. R., Burston, J. J., Woodhams, S. G. & Chapman, V. 2012 Dynamic changes to the endocannabinoid system in models of chronic pain. Phil. Trans. R. Soc. B 367, 3300-3311. (doi:10.1098/rstb.2011.0390)
39. Sang, N., Zhang, J. & Chen, C. 2006 PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J. Physiol. 572, 735-745. (doi:10.1113/jphysiol.2006.105569)
40. Skaper, S. D. & Facci, L. 2012 Mast cell-glia axis in neuroinflammation and therapeutic potential of theanandamide congener palmitoylethanolamide. Phil.Trans. R. Soc. B 367, 3312-3325. (doi:10.1098/rstb.2011.0391)
41. Bishop, N. A., Lu, T. & Yankner, B. A. 2010 Neural mechanisms of ageing and cognitive decline. Nature 464, 529-535. (doi:10.1038/nature08983)
42. Bilkei-Gorzo, A. 2012 The endocannabinoid system in normal and pathological brain ageing. Phil. Trans. R. Soc. B 367, 3326-3341. (doi:10.1098/rstb.2011.0388)
43. Brailoiu, G. C., Oprea, T. I., Zhao, P., Abood, M. E. & Brailoiu, E. 2011 Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J. Biol. Chem. 286, 29166-29174. (doi:10.1074/jbc.M110.217463)
44. Noonan, J., Tanveer, R., Klompas, A., Gowran, A., McKiernan, J. & Campbell, V. A. 2010 Endocannabinoids prevent b-amyloid-mediated lysosomal destabilization in cultured neurons. J. Biol. Chem. 285, 38543-38554. (doi:10.1074/jbc.M110.162040)
45. Nunn, A., Guy, G. & Bell, J. D. 2012 Endocannabinoids in neuroendopsychology: multiphasic control of mitochondrial function. Phil. Trans. R. Soc. B 367, 3342-3352. (doi:10.1098/rstb.2011.0393)
46. Pacher, P., Bátkai, S. & Kunos, G. 2006 The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389-462. (doi:10.1124/pr.58.3.2)
47. Pertwee, R. G. 2012 Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Phil. Trans. R. Soc. B 367, 3353-3363. (doi:10.1098/rstb.2011.0381)
48. Gaoni, Y. & Mechoulam, R. 1964 Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646-1647. (doi:10.1021/ja01062a046)
49. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. 2009 Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 30, 515-527. (doi:10.1016/j.tips.2009.07.006)
50. Agurell, S., Carlsson, S., Lindgren, J. E., Ohlsson, A., Gillespie, H. & Hollister, L. 1981 Interactions of d 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37, 1090-1092.(doi:10.1007/BF02085029)
51. Martín-Moreno, A. M. et al. 2012 Prolonged oral cannabinoid administration prevents neuroinflammation, lowers b-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation 9, 8.(doi:10.1186/1742-2094-9-8)
52. Sagredo, O., Pazos, M. R., Valdeolivas, S. & Fernandez Ruiz, J. 2012 Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Pat. CNS Drug Discov. 7, 41-48. (doi:10.2174/157488912798842278)
53. Levin, R. et al. In press. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Curr. Pharm. Des.